Graham: Doing nothing on drug prices 'unacceptable'

Graham: Doing nothing on drug prices 'unacceptable'
© Stefani Reynolds

Senate Judiciary Committee Chairman Lindsey GrahamLindsey Olin GrahamGraham says he shares Kurdish 'concerns' over cease-fire Majority of Americans believe Trump's Syria move has damaged US reputation: poll Senate GOP braces for impeachment trial 'roller coaster' MORE (R-S.C.) said Tuesday that he expects Congress to take action this year to lower drug prices by cracking down on drug companies that delay the patent system to extend their monopolies.

“I expect us to do something on patents and prescription drugs this year,” Graham said at a Judiciary Committee hearing. “I don’t know where the sweet spot is but doing nothing is unacceptable.”

In what could be a troubling sign for the drug industry, a number of senators from both parties called for action on Tuesday to restrict drug companies from using techniques to keep their prices high by finding ways to extend their monopolies on a drug.

ADVERTISEMENT

Lowering drug prices is seen as a rare possible area of bipartisan cooperation in Congress this year, with both Democrats and President TrumpDonald John TrumpFlorida GOP lawmaker says he's 'thinking' about impeachment Democrats introduce 'THUG Act' to block funding for G-7 at Trump resort Kurdish group PKK pens open letter rebuking Trump's comparison to ISIS MORE calling for action on the issue. Republican lawmakers have been the major question mark, but many called for at least some action on Tuesday.

Sen. Joni ErnstJoni Kay ErnstGOP cautions Graham against hauling Biden before Senate Farmers: New Trump ethanol proposal reneged on previous deal Overnight Energy: Farmers say EPA reneged on ethanol deal | EPA scrubs senators' quotes from controversial ethanol announcement | Perry unsure if he'll comply with subpoena | John Kerry criticizes lack of climate talk at debate MORE (R-Iowa) called it “crap” and “horrible” that a drug company, Allergan, in 2017 tried to shield its patents on a drug by transferring them to a Native American tribe.

Sen. John CornynJohn CornynTrump slams 'very dumb' O'Rourke for proposals on guns, tax exempt status for churches GOP cautions Graham against hauling Biden before Senate Succession at DHS up in the air as Trump set to nominate new head MORE (R-Texas) said it seemed “anti-competitive” that drug companies amass dozens of patents on a single drug as a way to fend off competition, and proposed giving the Federal Trade Commission authority to police the practice.

Sen. Dick DurbinRichard (Dick) Joseph DurbinSenate GOP braces for impeachment trial 'roller coaster' Trump judicial nominee delayed amid GOP pushback Schumer seeks focus on health care amid impeachment fever MORE (D-Ill.) expressed hope for bipartisan action after listening to his GOP colleagues, saying, “we are dangerously close to building a bipartisan consensus about change.”

Graham, Ernst, Cornyn and Durbin are all up for reelection next year.

Still, lawmakers have not settled on which bills to move forward, and any action on drug prices risks opening up a highly charged debate on how far to go to crack down on pharmaceutical companies.

“I’ve been here 2 1/2 years and all we've done about this is talk,” said Sen. John KennedyJohn Neely KennedyMORE (R-La.).

But he said that, eventually, he thinks Congress will act.